207 Dendritic Cells Immunotherapy in the Treatment of Glioblastoma

INTRODUCTION: Immunotherapy is gradually being established as a relevant adjuvant therapy against cancer. Cell vaccination is a promising strategy for the treatment of glioblastoma (GBM). CarT and dendritic cells (DC) have been associated with partial response therapy in recent publications. METHODS: Clinical data were evaluated including overall survival, disease-free survival, global health scales, and quality of life in neuro-oncology. Analysis of overall survival and survival after recurrence and after vaccination is presented. Immunological panel with CD4/CD8 T-cell counts and lymphokines count were obtained on each vaccination session. RESULTS: A significant increase in overall survival was observed in the vaccinated group (33.16 ± 9.42 months, versus 13.56 ± 0.95 months in the previous group control (log rank p = 0.0021). The median overall survival from the first recurrence for the vaccinated population was 8.1 ± 1.9 months, and 5.0 ± 1.4 counted from the start of vaccination. The immunological data strengthen the importance of Th1 response pattern for tumor control, and Th-17 pattern linked to recurrence. CONCLUSION: The preliminary data support the safety and possible efficacy of DC vaccination in increasing overall survival in patients with recurrent GBM. The immune data provide important insights on the mechanisms beyond tumor control and recurrence.